期刊文献+

1,25-二羟维生素D_3对骨髓破骨细胞形成和破骨细胞分化因子mRNA表达的影响 被引量:11

Effects of 1,25-(OH)_2D_3 on stimulation of osteoclast formation and expression of ODF in murine marrow cell
下载PDF
导出
摘要 目的 :观察不同浓度的 1,2 5 - (OH) 2 D3 对骨髓单个核细胞诱导形成破骨细胞和对单个核细胞ODFmRNA表达的影响。进一步阐明骨吸收刺激因子在破骨细胞性骨吸收中的作用机制。方法 :应用不同浓度的 1,2 5 - (OH) 2 D3 ( 0、10 -10 、10 -8、10 -6mol/L)诱导大鼠破骨细胞的形成 ,观察形成破骨细胞的数目 ,并采用原位杂交技术检测骨髓细胞ODFmRNA的表达。结果 :随着 1,2 5 - (OH) 2 D3 浓度的增加 ,多核细胞计数增多 ;ODFmRNA表达的阳性信号显著增强。结论 :1,2 5 - (OH) 2 D3 通过调节骨髓细胞ODFmRNA的表达 ,影响破骨细胞的形成和功能 ,进而调节局部骨微环境内骨吸收与骨形成平衡的变化 ,影响骨组织改建。 AIM:To investigate the effects of 1,25-(OH) 2D 3 on stimulation of osteoclast cell formation and expression of ODF in murine marrow cell,and further clarify the mechanisms of osteoclastic bone resorption regulated by 1,25-(OH) 2D 3.METHODS:Investigate the influence of different concentrations of 1,25-(OH) 2D 3 (010 -10 ?10 -8 ?10 -6 mol/L)on the number of oteoclast formation.The effects of 1,25-(OH) 2D 3 on the expression of ODF in murine marrow cell was examined by in situ hybridzation technique.RESULTS:1,25-(OH) 2D 3 could induce recruitment of osteoclast cell.The number of oteoclast formation increased and the expression of ODF mRNA increased with increasing concentration of 1,25-(OH) 2D 3 (0?10 -10 ?10 -8 ?10 -6 mol/L).CONCLUSION:1,25-(OH) 2D 3 could modulate the recruitment of osteoclast and the expression of ODF mRNA in murine marrow cell,thus adjust the bone metabolism.
出处 《牙体牙髓牙周病学杂志》 CAS 2004年第4期183-185,共3页 Chinese Journal of Conservative Dentistry
基金 国家自然科学基金资助项目 (3 0 3 0 0 3 93 )
关键词 1 25-二羟维生素D3 破骨细胞分化因子 破骨细胞 1,25-(OH) 2D 3 osteoclast differentiation factor(ODF) Osteoclast
  • 相关文献

参考文献9

  • 1Quinn JM, Fujikawa Y, McGee JO,et al.Rodent osteoblast-like cells support osteoclastic differentiation of human cord blood monocytes in the presence of M-CSF and 1,25 dihydroxyvitamin D3[J].Int J Biochem Cell Biol,1997,29(1):173-178
  • 2张银刚,薛金山,刘,裴琦,李琼,廉凯.外源性玻璃酸钠对骨关节炎患者的血清及滑液中白介素1β和肿瘤坏死因子α的影响[J].中国临床康复,2002,6(8):1204-1205. 被引量:18
  • 3Han JC, Rae KP, Jang SK,et al.Effect of stemcell factor, interleukin-6, nitric oxide and ransforming growth factor-β on the osteoclast differentiation induced by by 1α,25-(OH) 2D3 in primary murine bone marrow cultures[J].Pharmacology & Toxicology,1
  • 4Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(2):309-319
  • 5Tsuda E,Goto M,Mochizuki S,et al.Isolation of a novel cytokine from human fibroblast that specifically inhibits osteoclastogenesis[J].Biochem Biophys Res Commun,1997,234(1):137-142
  • 6Yasuda H, Shima N, Nakagawa N, et al.A novel molecular mechanism modulating osteoclast differentiation and function[J].Bone,1999,25(1):109-113
  • 7Suda T. How is bone formed and resorbed ?- molecular mechanisms of bone formation and resorption[J].Rinsho Byori,2002,50(3):267-72
  • 8Horwood NT,Elliott J,Martin TJ,et al.Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells[J].Endocrinology,1998,139(11):4743-4746
  • 9白玉娣,杨富生.核因子κB受体活化剂研究进展[J].牙体牙髓牙周病学杂志,2003,13(7):415-417. 被引量:2

二级参考文献30

  • 1吴海山,钱齐荣,顾其胜.关节内注射透明质酸钠预防兔骨关节炎的实验研究[J].中华骨科杂志,1996,16(1):37-39. 被引量:93
  • 2[11]Darnay BG, Ni J, Moore PA, et al. Activation of NF-κR bv RANK requires tumor necrosis factor receptor - associated factor(TRAF)6 and NF- κB- inducing kinase. Identification ofa TRAF6 interaction motiff[ J ]. J Bio Chem , 1999,274:7724
  • 3[12]Lacey DL, Tinms E, Tan H. - L,et al. Osteoprotegerin Ligand is a cytokine that regulates osteoclast differentiation and activation [ J ]. Cell, 1998,93:165
  • 4[13]H ofbauer LC, Khosla S, Lacey DL,et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption [ J ]. J Bone Miner Res , 2000,15:2
  • 5[14]Nakashima T, Kobayashi Y, Yamasaki S,et al. Protein expression and functional difference of membrane- bound and solublereceptor activator of NF - kappa B ligand: modulation of the expression by osteotropic factors and cytokines [ J ]. Biochem Biophys Res Commun ,2000,275 ( 3 ) :768
  • 6[15]Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption[J]. Medscape Womens Health ,2000,5 ( 2 ) :5
  • 7[16]Shevde NK, Bendixen AC, Dienger KM,et al. Estrogens suppress RANK ligand - induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression[J]. Proc Natl Acad Sci USA,2000,97 ( 14 ): 7829
  • 8[17]Mukohyama H, Ransjo M, Taniguchi H,et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase- activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK[J]. Biochm Biophys Res Commun ,2000 ,271:158
  • 9[18]Oyajobi BO, Anderson DM,Traianedes K,et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaBIgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy[J]. Cancer Res,2001,61 ( 6 ): 2572
  • 10[1]Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor - κB ligand and osteoprotegerin [ J ]. Cancer,2001,92( 3 ) :460

共引文献18

同被引文献150

引证文献11

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部